Company: Harpoon Therapeutics Inc.
Job title: CSO
Dr. Wesche joined Harpoon Therapeutics with 20 years of biotech experience focused on target validation, drug discovery and drug development as well as multi-site project management in the fields of oncology and inflammation. His previous role was as scientific director at Amgen where he was responsible for cross-functional organization and coordination of the next generation BiTE platform, the industry’s leading T-cell engaging antibody platform. He also led several drug discovery projects through pre-clinical development. Dr. Wesche is co-author of numerous publications and several US patents. Dr. Wesche received his PhD, summa cum laude, in biochemistry and Immunology from the University of Hannover, Germany.
TriTACs – Development Challenges and Opportunities for Novel T Cell Engagers 9:00 am
• T cell engager background: work well in liquid tumors, limited success in solid tumors so far • Analysis of differences: targets space, tumor microenvironment, drug exposures • Considerations for target selection and platform design to address these challenges • Description of the TriTAC platform • End with an update on the lead program, HPN424,…Read more
day: Day One